ISELIN, N.J., Sept. 3, 2015 /PRNewswire/ -- Echo
Therapeutics, Inc. (NASDAQ: ECTE), a medical device company focused
on non-invasive continuous glucose monitoring (CGM) and associated
technologies, announced today that it will participate in the
Rodman & Renshaw 17th Annual Global Investment
Conference to be held at the St. Regis Hotel in New York City.
Scott Hollander, President &
Chief Executive Officer, will provide a corporate overview on
Thursday, September 10 at
2:10 pm Eastern Time. A live webcast
of the presentation can be accessed at the Investors section of
Echo's website at www.echotx.com, or you may use the following
link:
http://wsw.com/webcast/rrshq25/ecte
An archived version of this webcast will be available for 90
days following the presentation at the Investors section of
www.echotx.com.
About Echo Therapeutics
Echo Therapeutics is developing its non-invasive, wireless,
continuous glucose monitoring (CGM) system. A significant
opportunity exists for the Company's CGM to be used in the
outpatient diabetes market and in the fitness, weight loss and
personal lifestyle wearable-health space. A longer-term opportunity
also exists in the hospital settings. Echo developed its
needle-free skin preparation device as a platform technology that
allows for enhanced skin permeation enabling extraction of
analytes, such as glucose, and enhanced delivery of topical
pharmaceuticals.
Cautionary Statement Regarding Forward Looking
Statements
The statements in this press release that are not historical
facts may constitute forward-looking statements that are based on
current expectations and are subject to risks and uncertainties
that could cause actual future results to differ materially from
those expressed or implied by such statements. Those risks and
uncertainties include, but are not limited to, risks related to
regulatory approvals and the success of Echo's clinical studies,
the safety and efficacy of Echo's CGM System, the failure of future
development and preliminary marketing efforts related to Echo's CGM
System, Echo's ability to secure additional commercial partnering
arrangements, risks and uncertainties relating to Echo's and its
partners' ability to develop, market and sell Echo's CGM System,
the availability of substantial additional equity or debt capital
to support its research, development and product commercialization
activities, and the success of its research, development,
regulatory approval, marketing and distribution plans and
strategies, including those plans and strategies related to its CGM
System. These and other risks and uncertainties are identified and
described in more detail in Echo's filings with the Securities and
Exchange Commission, including, without limitation, its Annual
Report on Form 10-K for the year ended December 31, 2014, its Quarterly Reports on Form
10-Q, and its Current Reports on Form 8-K. Echo undertakes no
obligation to publicly update or revise any forward-looking
statements.
For More Information:
Christine H.
Olimpio
Director, Investor Relations and Corporate Communications
(732)
549-0128
Connect With Us:
- Visit our website at
www.echotx.com
- Follow us on Twitter at www.twitter.com/echotx
- Join us on Facebook at www.facebook.com/echotx
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/echo-therapeutics-to-present-at-the-rodman--renshaw-17th-annual-global-investment-conference-300137465.html
SOURCE Echo Therapeutics, Inc.